Business Context and Reporting Period
This Form 6-K filing by Farmmi, Inc. covers the month of March 2022. The report details significant corporate governance changes, specifically the resignation of the Chief Financial Officer and the appointment of a successor, alongside updates on subsidiary restructuring and the formation of new entities.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate events rather than financial performance data.
Material Changes and Corporate Events
- Executive Leadership Change: Mr. Wenhua Liu resigned as CFO effective March 22, 2022, citing personal reasons with no disagreement with the registrant. Ms. Lingge Wu was appointed as the new CFO effective immediately.
- Compensation Terms: Ms. Wu's employment agreement includes a base compensation of RMB 250,000 per year and reimbursement of reasonable expenses. The agreement allows for termination with 30 days' notice or immediately for cause.
- New Entity Formation: In January 2022, the company formed two limited partnerships: Lishui Yitang Shangke Medical and Health Technology Partnership and Lishui Yifeng Yilong Medical Technology Development Partnership. Both focus on healthcare and are managed by Lishui Yifeng Healthcare Technology Co., Ltd.
- Subsidiary Restructure: Effective February 10, 2022, Farmmi (Hangzhou) Ecological Agriculture Development Co., Ltd. transferred all equity of Zhejiang Farmmi Agricultural Supply Chain Co., Ltd. to Zhejiang Farmmi Agricultural Science and Technology Group Co. Ltd., making the latter the direct parent of the supply chain entity.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard disclosure of executive turnover and corporate restructuring. The resignation of the CFO is explicitly stated as not involving any disagreement with the company.
Investor Verification Checklist
- Verify the background and qualifications of the new CFO, Ms. Lingge Wu, particularly her tenure within the company since 2017.
- Confirm the strategic rationale behind the formation of the two new healthcare-focused partnerships in January 2022.
- Review the impact of the February 2022 subsidiary equity transfer on the company's consolidated financial reporting structure.
- Monitor future filings for the first financial results under the new CFO's leadership.